In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
CBR-5884 is a selective inhibitor of 3-phosphoglycerate dehydrogenase (PHGDH) with IC50 of 7 μM. PHGDH catalyzes the first committed step of serine biosynthesis, is overexpressed in tumors and cancer cell lines via focal amplification and nuclear factor erythroid-2-related factor 2 (NRF2)-mediated up-regulation. So CBR-5884 can inhibit de novo serine synthesis in cancer cells.
CBR5884 selectively inhibits the proliferation of breast and melanoma cancer lines that have a high propensity for serine synthesis but has no effect on lines that rely on extracellular serine uptake. CBR-5884 is a noncompetitive and time-dependent inhibitor of PHGDH and disrupts its oligomerization state. The dose at which CBR-5884 has an effect on serine labeling was consistent with the in vitro biochemical IC50 of 33 ± 12 μM for PHGDH. At such concentrations, CBR-5884 has no effect on two other NAD+-dependent dehydrogenases, lactate dehydrogenase (LDH) and MDH1. The Ki value are 50 ± 20 μM and 50 ± 3 μM for 3-PG and NAD+, respectively. CBR-5884 is not generally cytotoxic at concentrations up to 40 μM as determined by two independent cellular viability assays. Treating the breast lines with CBR-5884 in serine-replete media inhibited growth of the four lines that grew without extracellular serine in a dose-dependent manner, with growth inhibition ranging from 35% to 60% at 30 μM CBR-5884. Serine depletion increases the efficacy of CBR-5884 in lines already sensitive under serine-replete conditions as evidenced by an 80–90% decrease in proliferation with 30 μM CBR-5884. 
1.Identification of a small molecule inhibitor of 3-phosphoglycerate dehydrogenase to target serine biosynthesis in cancers. Proc Natl Acad Sci U S A. 2016 Feb 16;113(7):1778-83.
|Physical Appearance||A solid|
|Storage||Store at -20°C|
|Solubility||≥16.8mg/mL in DMSO|
|Chemical Name||ethyl 5-(furan-2-carboxamido)-3-methyl-4-thiocyanatothiophene-2-carboxylate|